RU2603140C2 - Соединения имидазотриазинона - Google Patents
Соединения имидазотриазинона Download PDFInfo
- Publication number
- RU2603140C2 RU2603140C2 RU2013118362/04A RU2013118362A RU2603140C2 RU 2603140 C2 RU2603140 C2 RU 2603140C2 RU 2013118362/04 A RU2013118362/04 A RU 2013118362/04A RU 2013118362 A RU2013118362 A RU 2013118362A RU 2603140 C2 RU2603140 C2 RU 2603140C2
- Authority
- RU
- Russia
- Prior art keywords
- imidazo
- trans
- alkyl
- triazin
- pyran
- Prior art date
Links
- 0 *C(*)N(CC1*)CC1C(NC1=O)=N[n]2c1cnc2* Chemical compound *C(*)N(CC1*)CC1C(NC1=O)=N[n]2c1cnc2* 0.000 description 4
- VMMIDYYLWGCUFX-UHFFFAOYSA-N CC(CNC1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CNC1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 VMMIDYYLWGCUFX-UHFFFAOYSA-N 0.000 description 4
- BGBNHMFVGJJHAQ-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CN)C1=O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CN)C1=O BGBNHMFVGJJHAQ-UHFFFAOYSA-N 0.000 description 3
- JXILLBAMGVRSCN-UHFFFAOYSA-N CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CN(Cc3ccccc3)C1)NC2=O)(=O)=O Chemical compound CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CN(Cc3ccccc3)C1)NC2=O)(=O)=O JXILLBAMGVRSCN-UHFFFAOYSA-N 0.000 description 2
- RPZAAFUKDPKTKP-UHFFFAOYSA-N COCN(Cc1ccccc1)C[Si](C)(C)C Chemical compound COCN(Cc1ccccc1)C[Si](C)(C)C RPZAAFUKDPKTKP-UHFFFAOYSA-N 0.000 description 2
- MSFVEEFXECBJPG-UHFFFAOYSA-N ClCc1ncccn1 Chemical compound ClCc1ncccn1 MSFVEEFXECBJPG-UHFFFAOYSA-N 0.000 description 2
- JPSJBVNIHGQGNR-UHFFFAOYSA-N O=C(C1COCCC1)ON(C(CC1)=O)C1=O Chemical compound O=C(C1COCCC1)ON(C(CC1)=O)C1=O JPSJBVNIHGQGNR-UHFFFAOYSA-N 0.000 description 2
- DCVIMWRFFDRWJM-GSQGTZRGSA-N C/C=C/C(N([C@@H](CO1)c2ccccc2)C1=O)=O Chemical compound C/C=C/C(N([C@@H](CO1)c2ccccc2)C1=O)=O DCVIMWRFFDRWJM-GSQGTZRGSA-N 0.000 description 1
- JBBPETZJSIMBKB-UHFFFAOYSA-N CC(C)(C(ON(C(CC1)=O)C1=O)=O)OCc1ccccc1 Chemical compound CC(C)(C(ON(C(CC1)=O)C1=O)=O)OCc1ccccc1 JBBPETZJSIMBKB-UHFFFAOYSA-N 0.000 description 1
- YVYICMXHUOSHCD-UHFFFAOYSA-N CC(CN(Cc1c[n]2ncccc2n1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CN(Cc1c[n]2ncccc2n1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 YVYICMXHUOSHCD-UHFFFAOYSA-N 0.000 description 1
- PABAEZJKJVXISR-UHFFFAOYSA-N CC(CN(Cc1cccc(OC)n1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CN(Cc1cccc(OC)n1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 PABAEZJKJVXISR-UHFFFAOYSA-N 0.000 description 1
- HFIGSUCJPBFTMU-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(C(C)(C)OCc2ccccc2)=O)C1=O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(C(C)(C)OCc2ccccc2)=O)C1=O HFIGSUCJPBFTMU-UHFFFAOYSA-N 0.000 description 1
- RTSFLNQFAPBKOZ-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(C2COCCC2)=O)C1=O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(C2COCCC2)=O)C1=O RTSFLNQFAPBKOZ-UHFFFAOYSA-N 0.000 description 1
- GXQCWOAJLHKWTA-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(c(c(C)c2)ccc2F)=O)C1=O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CNC(c(c(C)c2)ccc2F)=O)C1=O GXQCWOAJLHKWTA-UHFFFAOYSA-N 0.000 description 1
- AZDIEPCCONVLKL-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C(C)(C)O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C(C)(C)O AZDIEPCCONVLKL-UHFFFAOYSA-N 0.000 description 1
- MVCWZQVACBTJHE-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCNCC1 Chemical compound CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCNCC1 MVCWZQVACBTJHE-UHFFFAOYSA-N 0.000 description 1
- UECRIHHANVMNHP-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CN(Cc1ccccc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 UECRIHHANVMNHP-UHFFFAOYSA-N 0.000 description 1
- KLQYKJMMAPSQCP-UHFFFAOYSA-N CC(CN(Cc1ccccc1)C1)C1C(OC)=O Chemical compound CC(CN(Cc1ccccc1)C1)C1C(OC)=O KLQYKJMMAPSQCP-UHFFFAOYSA-N 0.000 description 1
- PFBMCRPVEXEABN-UHFFFAOYSA-N CC(CN(Cc1nc2ccccc2cc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CN(Cc1nc2ccccc2cc1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 PFBMCRPVEXEABN-UHFFFAOYSA-N 0.000 description 1
- HKDOZTIOPAGQIS-UHFFFAOYSA-N CC(CN(Cc1ncccn1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 Chemical compound CC(CN(Cc1ncccn1)C1)C1C(NC1=O)=N[n]2c1cnc2C1CCOCC1 HKDOZTIOPAGQIS-UHFFFAOYSA-N 0.000 description 1
- OSPAFZLTSDSZGL-UHFFFAOYSA-N CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CN(Cc3ncccn3)C1)NC2=O)(=O)=O Chemical compound CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CN(Cc3ncccn3)C1)NC2=O)(=O)=O OSPAFZLTSDSZGL-UHFFFAOYSA-N 0.000 description 1
- WOWZRTFXRWWAPS-UHFFFAOYSA-N CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CNC1)NC2=O)(=O)=O Chemical compound CCS(N(CC1)CCC1c1ncc2[n]1N=C(C1C(C)CNC1)NC2=O)(=O)=O WOWZRTFXRWWAPS-UHFFFAOYSA-N 0.000 description 1
- OIWHGYGUHGWJOI-UHFFFAOYSA-N CCc1n[n](cccc2)c2n1 Chemical compound CCc1n[n](cccc2)c2n1 OIWHGYGUHGWJOI-UHFFFAOYSA-N 0.000 description 1
- HVGPUQMGDVWEGP-UHFFFAOYSA-N COc1cccc(CCl)n1 Chemical compound COc1cccc(CCl)n1 HVGPUQMGDVWEGP-UHFFFAOYSA-N 0.000 description 1
- BGBNHMFVGJJHAQ-JTDNENJMSA-N C[C@H](CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CN)C1=O Chemical compound C[C@H](CN(Cc1ccccc1)C1)C1C(N1)=NN=C(CN)C1=O BGBNHMFVGJJHAQ-JTDNENJMSA-N 0.000 description 1
- QWFKQOUZRAUJKO-HZULEVJDSA-N C[C@H](CN(Cc1ccccc1)C1)[C@@H]1C(N(C1O[C@H]1OC1)[C@@H]1c1ccccc1)=O Chemical compound C[C@H](CN(Cc1ccccc1)C1)[C@@H]1C(N(C1O[C@H]1OC1)[C@@H]1c1ccccc1)=O QWFKQOUZRAUJKO-HZULEVJDSA-N 0.000 description 1
- FNNHZCNVDAHYQW-DNVCBOLYSA-N C[C@H](CN(Cc1ccccc1)C1)[C@@H]1C(N1)=NN=C(CN(C(c2c3cccc2)=O)C3=O)C1=O Chemical compound C[C@H](CN(Cc1ccccc1)C1)[C@@H]1C(N1)=NN=C(CN(C(c2c3cccc2)=O)C3=O)C1=O FNNHZCNVDAHYQW-DNVCBOLYSA-N 0.000 description 1
- KZUXJRQQHJREGH-UHFFFAOYSA-N Cc1cc(F)ccc1C(Cl)=O Chemical compound Cc1cc(F)ccc1C(Cl)=O KZUXJRQQHJREGH-UHFFFAOYSA-N 0.000 description 1
- SRKDRUWQKBCCJU-UHFFFAOYSA-N ClCc1c[n]2ncccc2n1 Chemical compound ClCc1c[n]2ncccc2n1 SRKDRUWQKBCCJU-UHFFFAOYSA-N 0.000 description 1
- DDEAEWMDOSXKBX-UHFFFAOYSA-N ClCc1nc2ccccc2cc1 Chemical compound ClCc1nc2ccccc2cc1 DDEAEWMDOSXKBX-UHFFFAOYSA-N 0.000 description 1
- OPIZSFSIIDDGFE-BVSSSWPKSA-N N=C/C=C\c1nc(CCl)c[nH]1 Chemical compound N=C/C=C\c1nc(CCl)c[nH]1 OPIZSFSIIDDGFE-BVSSSWPKSA-N 0.000 description 1
- TWCRMRZDNRRWDC-UHFFFAOYSA-N O=C(c1c[o]cc1)ON(C(CC1)=O)C1=O Chemical compound O=C(c1c[o]cc1)ON(C(CC1)=O)C1=O TWCRMRZDNRRWDC-UHFFFAOYSA-N 0.000 description 1
- MIBCYYGVLHFYSD-UHFFFAOYSA-N OC(C1=COCCC1)=O Chemical compound OC(C1=COCCC1)=O MIBCYYGVLHFYSD-UHFFFAOYSA-N 0.000 description 1
- YEWPVCUHKJABMV-UHFFFAOYSA-N OC(C1COCCC1)=O Chemical compound OC(C1COCCC1)=O YEWPVCUHKJABMV-UHFFFAOYSA-N 0.000 description 1
- IHCCAYCGZOLTEU-UHFFFAOYSA-N OC(c1c[o]cc1)=O Chemical compound OC(c1c[o]cc1)=O IHCCAYCGZOLTEU-UHFFFAOYSA-N 0.000 description 1
- LFCWHDGQCWJKCG-UHFFFAOYSA-N OCc1nccnc1 Chemical compound OCc1nccnc1 LFCWHDGQCWJKCG-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N ON(C(CC1)=O)C1=O Chemical compound ON(C(CC1)=O)C1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38469410P | 2010-09-20 | 2010-09-20 | |
| US61/384,694 | 2010-09-20 | ||
| PCT/US2011/052399 WO2012040230A1 (en) | 2010-09-20 | 2011-09-20 | Imidazotriazinone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013118362A RU2013118362A (ru) | 2014-10-27 |
| RU2603140C2 true RU2603140C2 (ru) | 2016-11-20 |
Family
ID=44720178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013118362/04A RU2603140C2 (ru) | 2010-09-20 | 2011-09-20 | Соединения имидазотриазинона |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20120157458A1 (enExample) |
| EP (2) | EP3181566A1 (enExample) |
| JP (2) | JP5855109B2 (enExample) |
| CN (1) | CN103313988B (enExample) |
| AR (1) | AR083058A1 (enExample) |
| AU (2) | AU2011305568B2 (enExample) |
| BR (1) | BR112013008140A8 (enExample) |
| CA (1) | CA2811714C (enExample) |
| DK (1) | DK2619208T3 (enExample) |
| ES (1) | ES2610360T3 (enExample) |
| MX (1) | MX2013003093A (enExample) |
| PL (1) | PL2619208T3 (enExample) |
| RU (1) | RU2603140C2 (enExample) |
| TW (1) | TWI541244B (enExample) |
| UY (1) | UY33616A (enExample) |
| WO (1) | WO2012040230A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3181566A1 (en) * | 2010-09-20 | 2017-06-21 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| MX381326B (es) * | 2011-10-10 | 2025-03-12 | H Lundbeck As | Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos |
| EP2807163B1 (en) * | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| EP2828262A4 (en) | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
| CN102786525B (zh) | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| US20150284380A1 (en) | 2012-10-31 | 2015-10-08 | Bayer Cropscience Ag | Novel heterocyclic compounds as pest control agents |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JP2018508555A (ja) * | 2015-03-16 | 2018-03-29 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体 |
| TW201643167A (zh) * | 2015-04-22 | 2016-12-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之咪唑並三酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CA2990521C (en) | 2015-07-07 | 2023-10-10 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| IL295973A (en) | 2016-07-06 | 2022-10-01 | H Lundbeck As | pde9 inhibitors for the treatment of peripheral diseases |
| US10633382B2 (en) | 2016-10-18 | 2020-04-28 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors |
| RU2019108717A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| LT3532064T (lt) | 2016-10-28 | 2020-09-25 | H. Lundbeck A/S | Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui |
| HUE065158T2 (hu) * | 2017-05-26 | 2024-05-28 | Cardurion Pharmaceuticals Inc | PDE9 gátlószereinek elõállítására és alkalmazására szolgáló eljárások |
| BR112020024019A2 (pt) | 2018-05-25 | 2021-02-23 | Imara Inc. | monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona |
| KR20250108770A (ko) | 2018-08-31 | 2025-07-15 | 카듀리온 파마슈티칼스, 인크. | 겸상 세포 질환의 치료를 위한 pde9 억제제 |
| WO2020102374A1 (en) * | 2018-11-14 | 2020-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting of makap-pde4d3 complexes in neurodegenerative disease |
| KR102712818B1 (ko) | 2018-12-06 | 2024-09-30 | 한국화학연구원 | Pde9a 저해 활성을 가지는 화합물 및 이들의 의약 용도 |
| CA3155013A1 (en) * | 2019-10-21 | 2021-04-29 | Ki Ho Lee | Use of imidazopyrimidine or imidazotriazine compound for prevention, alleviation, or treatment of developmental disability |
| CN112724079A (zh) * | 2021-02-04 | 2021-04-30 | 康化（上海）新药研发有限公司 | 一种6-甲氧基吡啶甲酸甲酯的合成方法 |
| GB2632307A (en) * | 2023-08-02 | 2025-02-05 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002098873A1 (en) * | 2001-06-01 | 2002-12-12 | Bayer Healthcare Ag | 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| WO2003037432A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| WO2004096811A1 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Pde9 inhibitors for treating type 2 diabetes, metabokic syndrome, and cardiovascular disease |
| RU2260593C2 (ru) * | 1997-11-12 | 2005-09-20 | Байер ХельсКер АГ | 2-фенилзамещенные имидазотриазиноны, способ их получения и фармацевтическая композиция на их основе, обладающая свойствами ингибитора фосфодиэстеразы i,ii и v |
| WO2008139293A1 (en) * | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| HU227841B1 (en) | 1997-11-12 | 2012-05-02 | Bayer Pharma AG | 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof |
| US7087605B2 (en) | 2001-06-01 | 2006-08-08 | Bayer Aktiengesellschaft | 5-Ethyl-imidazotriazinones |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
| WO2006127368A2 (en) | 2005-05-20 | 2006-11-30 | Lexicon Genetics Incorporated | Methods for synthesizing imidazotriazinones |
| US20090163521A1 (en) | 2005-06-28 | 2009-06-25 | Orchid Research Laboratories Limited | Novel Pyrazolopyrimidinone Derivatives |
| CN102131801B (zh) | 2008-06-25 | 2015-04-08 | 福拉姆医药股份有限公司 | 1,2-二取代的杂环化合物 |
| EP3181566A1 (en) | 2010-09-20 | 2017-06-21 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| EP2807163B1 (en) | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
| EP2828262A4 (en) | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
-
2011
- 2011-09-20 EP EP16197573.5A patent/EP3181566A1/en not_active Withdrawn
- 2011-09-20 JP JP2013530234A patent/JP5855109B2/ja not_active Expired - Fee Related
- 2011-09-20 BR BR112013008140A patent/BR112013008140A8/pt not_active IP Right Cessation
- 2011-09-20 ES ES11761793.6T patent/ES2610360T3/es active Active
- 2011-09-20 RU RU2013118362/04A patent/RU2603140C2/ru not_active IP Right Cessation
- 2011-09-20 EP EP11761793.6A patent/EP2619208B1/en not_active Not-in-force
- 2011-09-20 AU AU2011305568A patent/AU2011305568B2/en not_active Ceased
- 2011-09-20 CA CA2811714A patent/CA2811714C/en not_active Expired - Fee Related
- 2011-09-20 MX MX2013003093A patent/MX2013003093A/es active IP Right Grant
- 2011-09-20 US US13/237,795 patent/US20120157458A1/en not_active Abandoned
- 2011-09-20 PL PL11761793T patent/PL2619208T3/pl unknown
- 2011-09-20 WO PCT/US2011/052399 patent/WO2012040230A1/en not_active Ceased
- 2011-09-20 TW TW100133825A patent/TWI541244B/zh not_active IP Right Cessation
- 2011-09-20 UY UY0001033616A patent/UY33616A/es unknown
- 2011-09-20 AR ARP110103426A patent/AR083058A1/es unknown
- 2011-09-20 DK DK11761793.6T patent/DK2619208T3/en active
- 2011-09-20 CN CN201180055157.9A patent/CN103313988B/zh not_active Expired - Fee Related
-
2014
- 2014-07-17 US US14/334,073 patent/US9540380B2/en not_active Expired - Fee Related
-
2015
- 2015-12-08 JP JP2015239514A patent/JP2016104747A/ja active Pending
-
2016
- 2016-02-16 AU AU2016200970A patent/AU2016200970A1/en not_active Abandoned
- 2016-12-07 US US15/371,935 patent/US20170152265A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2260593C2 (ru) * | 1997-11-12 | 2005-09-20 | Байер ХельсКер АГ | 2-фенилзамещенные имидазотриазиноны, способ их получения и фармацевтическая композиция на их основе, обладающая свойствами ингибитора фосфодиэстеразы i,ii и v |
| WO2002098873A1 (en) * | 2001-06-01 | 2002-12-12 | Bayer Healthcare Ag | 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| WO2003037432A1 (en) * | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| WO2004096811A1 (en) * | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Pde9 inhibitors for treating type 2 diabetes, metabokic syndrome, and cardiovascular disease |
| WO2008139293A1 (en) * | 2007-05-11 | 2008-11-20 | Pfizer Inc. | Amino-heterocyclic compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011305568B2 (en) | 2015-12-10 |
| US20170152265A1 (en) | 2017-06-01 |
| CN103313988A (zh) | 2013-09-18 |
| US20140330014A1 (en) | 2014-11-06 |
| TW201217381A (en) | 2012-05-01 |
| AR083058A1 (es) | 2013-01-30 |
| WO2012040230A1 (en) | 2012-03-29 |
| BR112013008140A2 (pt) | 2017-12-05 |
| CA2811714C (en) | 2017-11-21 |
| TWI541244B (zh) | 2016-07-11 |
| UY33616A (es) | 2012-04-30 |
| JP2016104747A (ja) | 2016-06-09 |
| HK1187908A1 (en) | 2014-04-17 |
| ES2610360T3 (es) | 2017-04-27 |
| MX2013003093A (es) | 2013-10-28 |
| EP3181566A1 (en) | 2017-06-21 |
| EP2619208B1 (en) | 2016-11-09 |
| BR112013008140A8 (pt) | 2018-04-03 |
| CN103313988B (zh) | 2016-06-08 |
| DK2619208T3 (en) | 2017-01-30 |
| JP2013540755A (ja) | 2013-11-07 |
| EP2619208A1 (en) | 2013-07-31 |
| PL2619208T3 (pl) | 2017-03-31 |
| US20120157458A1 (en) | 2012-06-21 |
| JP5855109B2 (ja) | 2016-02-09 |
| CA2811714A1 (en) | 2012-03-29 |
| RU2013118362A (ru) | 2014-10-27 |
| AU2011305568A1 (en) | 2013-04-04 |
| US9540380B2 (en) | 2017-01-10 |
| AU2016200970A1 (en) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2619208B1 (en) | Imidazotriazinone compounds | |
| US9969742B2 (en) | Imidazotriazinone compounds | |
| TWI829676B (zh) | 噁二唑暫時受體電位通道抑制劑 | |
| EP3204387B1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| JP2016537369A (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| KR20150027267A (ko) | LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘 | |
| JP2019532985A (ja) | ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 | |
| JP2018513184A (ja) | Ｐｄｅ１阻害剤としてのイミダゾトリアジノン | |
| JP2024545591A (ja) | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 | |
| JP2019532990A (ja) | ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン化合物 | |
| JP2019532983A (ja) | ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン化合物 | |
| KR20260057425A (ko) | 화합물, 조성물, 및 방법 | |
| HK1187908B (en) | Imidazotriazinone compounds | |
| HK1234039A1 (en) | Imidazotriazinone compounds | |
| EP4640274A1 (en) | Lpar1 inhibitors | |
| CN117659023A (zh) | 吡啶乙酰胺类衍生物、包含其的药物组合物及其医药用途 | |
| HK40031697B (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors | |
| HK40031697A (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180921 |